Skip to main content
SpringerLink
Log in

Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease

  • Research Letter to the Editor
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Anelli MG, Franceschini R, Menicacci C, Galeazzi M, Selmi C, Rigante D (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet’s disease. Autoimmun Rev 14(1):1–9. https://doi.org/10.1016/j.autrev.2014.08.008

    Article  CAS  PubMed  Google Scholar 

  2. Kone-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, Kuemmerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, Letierce A, Tran TA, Committee P-BIE (2011) Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 50(1):184–188. https://doi.org/10.1093/rheumatology/keq324

    Article  Google Scholar 

  3. Lopalco G, Lucherini OM, Vitale A, Talarico R, Lopalco A, Galeazzi M, Lapadula G, Cantarini L, Iannone F (2015) Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for Behcet’s disease. Medicine (Baltimore) 94(42):e1858. https://doi.org/10.1097/MD.0000000000001858

    Article  CAS  Google Scholar 

  4. Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behcet syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107–119. https://doi.org/10.1038/nrrheum.2017.208

    Article  CAS  PubMed  Google Scholar 

  5. Lopalco G, Lucherini OM, Lopalco A, Venerito V, Fabiani C, Frediani B, Galeazzi M, Lapadula G, Cantarini L, Iannone F (2017) Cytokine signatures in mucocutaneous and ocular Behcet’s disease. Front Immunol 8:200. https://doi.org/10.3389/fimmu.2017.00200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95(24):e3863. https://doi.org/10.1097/MD.0000000000003863

    Article  CAS  Google Scholar 

  7. Emmi G, Silvestri E, Squatrito D, D’Elios MM, Ciucciarelli L, Prisco D, Emmi L (2014) Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med 9(3):257–265. https://doi.org/10.1007/s11739-013-1036-5

    Article  PubMed  Google Scholar 

  8. Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, Urban ML, Frediani B, Galeazzi M, Iannone F, Rigante D, Cantarini L (2017) Adalimumab effectiveness in Behcet’s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36(2):451–455. https://doi.org/10.1007/s10067-016-3417-4

    Article  PubMed  Google Scholar 

  9. Braun J, Kudrin A (2015) Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy 7(2):73–87. https://doi.org/10.2217/imt.14.109

    Article  CAS  PubMed  Google Scholar 

  10. Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehoj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sorensen MV, Andersen LS, Gron KL, Krogh NS, Pedersen L, Hetland ML, All Departments of Rheumatology in D (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76(8):1426–1431. https://doi.org/10.1136/annrheumdis-2016-210742

    Article  CAS  PubMed  Google Scholar 

  11. Dinçses E, Esatoğlu S, Seyahi E, Melikoğlu M, Fresko I, Hamuryudan V, Uçar D, Özyazgan Y, Kutlubay Z, Mat C, Yurdakul S, Hatemi G (2017) AB0558 biosimilar infliximab for Behçet’s syndrome. Ann Rheum Dis 76(Suppl 2):1246–1248. https://doi.org/10.1136/annrheumdis-2017-eular.6019

    Article  Google Scholar 

  12. Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O (2017) Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet’s disease after switching from infliximab originator. Eur J Rheumatol 4(4):288–290. https://doi.org/10.5152/eurjrheum.2017.16112

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol 31(7):1362–1368

    CAS  PubMed  Google Scholar 

  14. Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, Abud-Mendoza C, Navarra S, Kadinov V, Sariego IG, Hong SS, Lee SY, Park W (2016) A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 18:82. https://doi.org/10.1186/s13075-016-0981-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J (2016) Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther 18:25. https://doi.org/10.1186/s13075-016-0930-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm 3:1–6. https://doi.org/10.1080/09273948.2017.1391297

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Professor Giovanni Lapadula for his valuable insights.

Author information

Author notes

  1. Giuseppe Lopalco and Vincenzo Venerito equally contributed to this work.

Authors and Affiliations

  1. Rheumatology Unit, Department of Emergency and Organ Transplantation, Polyclinic Hospital, Piazza G. Cesare 11, 70124, Bari, Italy

    Giuseppe Lopalco, Vincenzo Venerito & Florenzo Iannone

  2. Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, University of Siena, Siena, Italy

    Luca Cantarini

  3. Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy

    Giacomo Emmi & Domenico Prisco

Authors
  1. Giuseppe Lopalco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincenzo Venerito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Cantarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giacomo Emmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Domenico Prisco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florenzo Iannone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Lopalco.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from all the patients.

Additional information

This article is part of the topical collection “Behcet Disease”.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lopalco, G., Venerito, V., Cantarini, L. et al. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease. Intern Emerg Med 14, 719–722 (2019). https://doi.org/10.1007/s11739-018-1970-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-018-1970-3

Search

Navigation